Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07441395 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

Study acronym: SIERRA1
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Primary completion date: Aug 2027 to Jun 2027 · Completion date: Nov 2027 to Sep 2027 · 1 morev2 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Primary completion date: Aug 2027 to Jun 2027
    • Completion date: Nov 2027 to Sep 2027
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to see how well different doses of soquelitinib work in participants with atopic dermatitis (AD) as compared to a placebo (pill with no medicine in it). To check this, the study doctors will examine participants' skin regularly to track how their AD changes during the study. The study doctors will see how safe soquelitinib is by tracking side effects among participants. They will also check "tolerability," which means how well the participants can handle soquelitinib and whether any potential side effects are manageable for them. To understand how well soquelitinib works, it will be compared with a placebo. Placebo is a substance that looks like soquelitinib but contains no active medicine in it. Participants will: * Take study treatment (soquelitinib or placebo) every day for 12 weeks * Visit the clinic for check-ups and tests every week for the first 2 weeks then every 2 weeks during the treatment period, and then return for follow-up visits 30, 60, and 90 days after the last dose of study treatment
Trial Details
NCT Number NCT07441395
Lead Sponsor Corvus Pharmaceuticals, Inc.
Conditions Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Eczema, Atopic
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov